dickie3times
17 May 2018
Hardman - A Pivotal Year ***Management indicated that discussions are underway with several potentialpartners for the further development of VAL401.Pre-clinical developments***[link] trial updateVAL201High safety and tolerability, plus some early evidence of efficacy, has been observedin the Phase I/II trial in advanced/metastatic prostate cancer for the peptide inhibitorthat possesses a distinctive mode of action on the androgen receptor. Consequently,the research ethic committee, in consultation with the MHRA, decided to escalateboth the dose and frequency of administration, thereby raising the potential forVAL201 to show anti-cancer efficacy. Headline data are expected during 2018.VAL401The reformulated oral version of risperidone allows specific targeting of cancer cellshas completed a pilot Phase II trial in late-stage lung cancer patients. Results werevery favourable, with VAL401 achieving an overall response rate of 60% andimproved the quality of life in patients with late-stage disease. In addition, there wassome evidence to show that VAL401 improves disease symptoms (pain and fatigue),suggesting that it has a palliative effect, and making it a good candidate for acombination study. A proposed Phase III trial in ca.200 late-stage NSCLC patientswith and without standard-of-care will be run either with or by a partner. ****Management indicated that discussions are underway with several potentialpartners for the further development of VAL401.Pre-clinical developments***VAL301The reformulated version of VAL201, targeting the gynaecological disorderendometriosis, which is hypothesised to have a lowerside effect potential comparedto current standard-of-care. VAL301 is currently undergoing late-stage pre-clinicalstudies with the aim of having a complete pre-clinical package with the optimalformulation during 2018. VAL is expected to submit an IND to start clinical trials in2018.VAL101Through a consortium of partners, led by ValiRx, the manufacturing process for theGeneICE platform has been optimised. This has paved the way for accelerated preclinicaldevelopment of a new version of VAL101 that targets the gene expressingBcl2. Having shown that VAL101 produced programmed cell death (apoptosis) incancer cell models, the product is now being prepared for testing in clinical trials.
clockwurktangerine
16 May 2018
Itaconix a proper bio Val don't have any partners except YA!Itaconix plc ("Itaconix" or the "Company"
Itaconix and AkzoNobel move from the technical evaluation phase to defining a joint marketing effort for Itaconix bio-based chelates
clockwurktangerine
16 May 2018
To or jv? NEITHER, NO RESPECTABLE INVESTOR IS INTERESTED IN A FEW RANDOM COMPOUNDS, AS YET UNTESTED...
Tired and Confused
15 May 2018
2p here we come? In the absence of news and 10% of the money raised on last placing already gone (based on previous burn rate) we are no further forward and one step closer to the next dilutional financial event.Looks like the BOD will need to issue themselves some more options, 4p doesn't look lucrative enough now 
Still plan to average down at 2p because we will see 4p to 6p at some point so that the 'snouts in the trough' money people can get out at a slim profit all at the expense of existing long term shareholders.AIMHO and DYOR
Tired and Confused
11 May 2018
Re: Question You're quite right, the way VAL finance the business requires them to create excitement about developments, that encourages spikes in the share price from time to time so that the 'snouts in the trough' money people can benefit from the warrants that are granted as part of the fees for setting up the ongoing finance for VAL. If the whole shady financing process (IMHO) doesn't pay off then the whole sorry gravy train comes to an end. This is an AIM issue and not just confined to VAL, many companies are at it, its a bleeping cottage industry!It is vital for them, it is vital for us as shareholders that this whole sorry financing fiasco continues until we get to an end game. Hopefully VAL will sell one of the compounds or get a JV or just get bought out some time soon, otherwise we are pretty much dependent on them raising money from any desperate, lenders of last resort in anyway they can. They are not going to continue without being paid(TOO much for the results delivered) are they?AIMHO and DYOR and I still think there is possible outcome for punters but it is frankly laughable to think this will be a multibagger. Dilution has long since put pay to that.
fredd1eboy
10 May 2018
Re: Question Hopefully before any value-added news their client will have sold the 50m shares to be placed on market Monday. Otherwise any lift will be short lived. What a "f" up.
Small Holding
10 May 2018
Re: Question If they were backed into a corner and had to withdraw those two resolutions, then it should at least focus their minds on getting a deal of some description agreed.I fully agree that everyone is sick to death of their endless promises of realising value, yet in reality the bandwagon keeps on rolling with nothing concrete being delivered, in terms of joint ventures etc.
Tired and Confused
10 May 2018
Re: Question I don't buy the 'we didn't have to withdraw it' theory.All evidence suggest when it comes to being ethical with investors VAL come up short. IMHOThey thought it would go through and all the information which 'caused' them to reconsider resolutions 6 and 7 was available before the day of the meeting so, why withdraw on the day?There is more to this than we are being told. Think we have reached the point where regardless whether it disgruntled PI's or institutional investors, we are all of the same opinion now. Enough is enough, JV, get bought out; fine. Endless stomping up of cash year after year has to stop.That's my view.In the end you haven't got a PLC business if ultimately you cannot provide a return on capital employed and deliver for investors. AIMHO and DYOR
Small Holding
10 May 2018
Re: Question T&C Many thanks for your comprehensive response"It is going to be very interesting from now on in. They are either going to announce the sale of one of the compounds to capitalise the company, announce a JV or 'take out' deal or, be back asking for more money in a few more weeks, yes, that's right weeks!"This was my next point but you have covered it in the above.orI have read on other boards that they didn't have to withdraw those two resolutions and that they could have still got them passed, what are your views on this?
Small Holding
10 May 2018
Question Excuse my ignorance but can anyone answer this question pleaseAs resolutions 6 & 7 were withdrawn at the AGM, does that mean that this last placing is the last Valirx can do, unless they put any potential future placings to a shareholder vote and hold an EGM?
clockwurktangerine
09 May 2018
Val Should never had had an ipo, and listed to turn Val owners into bod salaried!If they work along ucl.ac.uk then what a contrast in salaries!The initial days of a hyped up are gone.Now it is nitty gritty continuos dosh needed.Jv or to, just flipping talk!Useless...
Tired and Confused
08 May 2018
Very, very interesting!!!!! London, UK., 08 May 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that at its Annual General Meeting ("AGM" held earlier today, resolutions 1-5 were passed and resolutions 6 and 7 were withdrawn.Here resolutions 6 & 7 listed below.Resolution 6 – allotment of share capitalAt a General Meeting of the Company held on 21 December 2017, the directors were given authority to allot ordinary shares in the capital of theCompany up to a maximum nominal amount of two hundred and sixteen thousand four hundred and five pounds and forty one pence (£216,405.41),representing approximately 100 per cent. of the Company’s then issued ordinary share capital.The Board considers it appropriate that authority in respect of a similar percentage of the issued share capital be granted to allot ordinary sharesin the capital of the Company. Accordingly the Board is seeking authority to allot ordinary shares up to a maximum nominal amount of four hundredand seven thousand four hundred and sixty two pounds and seventy one pence (£407,462.71), representing the aggregate of 100 per cent. of theCompany’s issued ordinary share capital as at 10 April 2018 (the latest practicable date before publication of this letter), during the period up to theconclusion of the next AGM in 2019 or, if earlier the date 15 months after the date of the passing on the resolution.As at the date of this letter, the Company does not hold any ordinary shares in the capital of the Company in treasury.Resolution 7 – disapplication of statutory pre-emption rightsResolution 7 will empower the directors to allot ordinary shares in the capital of the Company for cash on a non-pre-emptive basis: 1 in connection with a rights issue or other pro-rata offer to existing shareholders; and 2 (otherwise than in connection with a rights issue) up to a maximum nominal value of four hundred and seven thousand four hundred and sixty two pounds and seventy one pence pounds (£407,462.71), representing 100 per cent. of the issued ordinary share capital of the Company as at 10 April 2018 (the latest practicable date before publication of this letter).The Board considers it appropriate to seek the levels of authority sought under Resolutions 6 and 7 in order to give the directors flexibility as theCompany moves to the next stage of its development. ENDWell it seems that they were likely to lose the request and thought better of it?It's crunch time for VAL now: the peanuts they raised on Friday do little more than tide them over. They need major funding urgently or they may have to sell one of the key assets to keep going, IMHO. Never mind, I'm sure it will trigger the 4p options/warrant and allow NOVUM to exercise the 1,800,000 warrant and get out with a profit. novumsecurities.com/#owltabs2Isn't it interesting, the BOD hold 0.47% of the share capital, 1,929.091 shares between them, impressive? NO. The last fundraising on Friday gave Novum a warrant for 1,800,000 shares at just 2.5p per share and that was just for a tiny fund raising. In one go, this fundraising gave away the equivalent of 93.3% of the total BOD's current shareholding. They like taking wages but sure don't want to share the risks of significant share ownership. For an 'investable Company' their personal commitment is p@thetic (IMHO) so, what do they know that we don't?Not looking very good for shareholders, but then, when has it ever looked good for us Have reduced my average down target to 2p after today's quite extraordinary news.AIMHO and DYOR
Tired and Confused
08 May 2018
What a laugh! RecommendationThe Board considers that the resolutions to be proposed at the AGM (the “Resolutions” will promote the success of the Company and are in the bestinterests of the Company and its shareholders as a whole. The directors unanimously recommend that you vote in favour of the Resolutions as they intendto do in respect of their own beneficial holdings which amount in aggregate to 1,929,091 shares representing approximately 0.47 per cent. of the existingissued ordinary share capital of the Company ENDIsn't it rather striking that for a Company with such shareholder potential and one that is NOW an investable proposition, that they have sunk so little of their own money into the Business and have granted themselves such cheap and undemanding options?AIMHO and DYOR
Small Holding
06 May 2018
AGM 8th May resolution 6 Resolution 6 – allotment of share capital At a General Meeting of the Company held on 21 December 2017, the directors were given authority to allot ordinary shares in the capital of the Company up to a maximum nominal amount of two hundred and sixteen thousand four hundred and five pounds and forty one pence (£216,405.41), representing approximately 100 per cent. of the Company’s then issued ordinary share capital. The Board considers it appropriate that authority in respect of a similar percentage of the issued share capital be granted to allot ordinary shares in the capital of the Company. Accordingly the Board is seeking authority to allot ordinary shares up to a maximum nominal amount of four hundred and seven thousand four hundred and sixty two pounds and seventy one pence (£407,462.71), representing the aggregate of 100 per cent. of the Company’s issued ordinary share capital as at 10 April 2018 (the latest practicable date before publication of this letter), during the period up to the conclusion of the next AGM in 2019 or, if earlier the date 15 months after the date of the passing on the resolution. The Total Number of shares with nominal value 0.1p in issue is 407,462,717 So once this is passed they will be able to continue the dilution by a further 100% next year by issuing another 407,462,717 shares if they so wish.
clockwurktangerine
05 May 2018
Val based at Ucl.ac.uk??? Blimee what a mix, civil service salaried amongst Val CEO bods!!!Read this on lse bord!!!
